

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on August 6, 2007

PATENT  
Attorney Docket No.: 020885-000720US  
Client Reference No.: UC 2002-437-3

TOWNSEND and TOWNSEND and CREW LLP

By:   
Judith Cotham

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

William E. Bunney, Jr. et al.

Application No.: 10/649,400

Filed: August 26, 2003

For: GENES INVOLVED IN  
NEUROPSYCHIATRIC DISORDERS

Confirmation No.: 6108

Examiner: Steven H. Standley

Art Unit: 1649

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or  
Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please  
deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Chris J. Ullsperger  
Reg. No. 48,006

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: 925-472-8895  
JS:jc

Substitute for form 1449A&B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/649,400
		<b>Filing Date</b>	August 26, 2003
		<b>First Named Inventor</b>	Bunney, William E.
		<b>Art Unit</b>	1649
		<b>Examiner Name</b>	Steven H. Standley
<b>Sheet</b>	1	<b>of</b>	1
		<b>Attorney Docket Number</b>	020885-000720US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BA	TORREY, <i>et al.</i> ; The Stanley Foundation brain collection and Neuropathology Consortium; Schizophrenia Research 44 (2000); 151-155.	<input type="checkbox"/>
	BB	LI, <i>et al.</i> ; Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions; <i>Human Molecular Genetics</i> ; (2004) Vol. 13, No. 6; 609-616.	<input type="checkbox"/>
	BC	EVANS, <i>et al.</i> ; Dysregulation of the fibroblast growth factor system in major depression; <i>PNAS</i> ; (2004) Vol. 101, 15506-15511.	<input type="checkbox"/>
	BD	CHOUDARY, <i>et al.</i> ; Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression; <i>PNAS</i> ; (2005) Vol. 102, 15653-15658.	<input type="checkbox"/>
	BE	NOVAK, <i>et al.</i> ; Increased Expression of Calcium Calmodulin-Dependent Protein Kinase II $\beta$ in Frontal Cortex in Schizophrenia and Depression; <i>SYNAPSE</i> (2006) 59:61-68.	<input type="checkbox"/>
	BF	IWAMOTO, <i>et al.</i> ; Gene Expression Profiling in Schizophrenia and Related Mental Disorders; <i>THE NEUROSCIENTIST</i> ; (2006) Vol. 12, 349-361.	<input type="checkbox"/>
	BG	BUNNEY, <i>et al.</i> ; Microarray Technology: A Review of New Strategies to Discover Candidate Vulnerability Genes in Psychiatric Disorders; <i>Am J Psychiatry</i> ; (2003) 160:4, 657-666.	<input type="checkbox"/>
	BH	ATZ, <i>et al.</i> ; Methodological considerations for gene expression profiling of human brain; <i>Journal of Neuroscience Methods</i> ; (2007)	<input type="checkbox"/>
	BI	MEXAL, <i>et al.</i> ; Brain pH has a significant impact on human postmortem hippocampal gene expression profiles; <i>Brain Research</i> ; (2006) 1106: 1-11.	<input type="checkbox"/>
	BJ	TOMITA <i>et al.</i> ; Effect of Agonal and Postmortem Factors on Gene Expression Profile: Quality Control in Microarray Analyses of Postmortem Human Brain; <i>BIOL PSYCHIATRY</i> ; (2004) 55:346-352.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.